Pembrolizumab plus lenvatinib for non-clear cell kidney cancer
Immunotherapy combinations are becoming the standard treatment for people with [...]
Immunotherapy combinations are becoming the standard treatment for people with [...]
Immunotherapy combinations are becoming the standard treatment after surgery for [...]
Further follow-up data from the phase 3 CLEAR study with [...]
Lenvatinib plus pembrolizumab has already been shown to improve survival [...]
The National Institute for Health and Care Excellence (NICE) has [...]
The phase 2 KEYNOTE-B61 study was presented at the recent [...]
Results from the phase 3 CLEAR studywere presented at the [...]
Maintaining good health-related quality of life is important for all [...]
In this study, the health-related quality of life (HRQoL) of [...]
In this video, Dr Bradley McGregor from the Dana-Farber Cancer [...]